Skip to main content
Back
DMPHF logo

Dermapharm Holding SE

Data quality: 100%
Overbought
DMPHF
OTC Healthcare Drug Manufacturers - Specialty & Generic
$39.56
$0.00 (0.00%)
Mkt Cap: 2.13B
Day Range
$39.56 $42.68
52-Week Range
$39.56 $42.68
Volume
476
50D / 200D Avg
$39.56 / $39.56
Prev Close
$39.56

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (626 peers)

Metric Stock Sector Median
P/E 18.7 0.4
P/B 3.5 2.9
ROE % 19.9 3.7
Net Margin % 9.6 3.9
Rev Growth 5Y % 10.4 10.0
D/E 1.6 0.2

Analyst Price Target

No analyst coverage available

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2029 $0.00
$0.00 – $0.00
 1.3 B 0
FY2028 $3.34
$3.28 – $3.39
 1.3 B 1
FY2027 $2.56
$2.51 – $2.60
 1.3 B 1

Key Takeaways

Revenue grew 10.44% annually over 5 years — strong growth
Earnings grew 82.44% over the past year
ROE of 19.90% — decent returns on equity
Generating 163.14M in free cash flow
PEG of 0.24 suggests growth is underpriced
Revenue growth is decelerating — 1Y growth trails 5Y average by 7.83%

Growth

Revenue Growth (5Y)
10.44%
Revenue (1Y)2.61%
Earnings (1Y)82.44%
FCF Growth (3Y)-19.14%

Quality

Return on Equity
19.90%
ROIC10.27%
Net Margin9.64%
Op. Margin18.37%

Safety

Debt / Equity
1.62
Current Ratio1.82
Interest Coverage3.71

Valuation

P/E Ratio
18.72
P/B Ratio3.52
EV/EBITDA13.78
Dividend Yield0.02%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 2.61% Revenue Growth (3Y) 7.34%
Earnings Growth (1Y) 82.44% Earnings Growth (3Y) -7.93%
Revenue Growth (5Y) 10.44% Earnings Growth (5Y) 7.30%
Profitability
Revenue (TTM) 1.18B Net Income (TTM) 113.79M
ROE 19.90% ROA 5.47%
Gross Margin 64.96% Operating Margin 18.37%
Net Margin 9.64% Free Cash Flow (TTM) 163.14M
ROIC 10.27% FCF Growth (3Y) -19.14%
Safety
Debt / Equity 1.62 Current Ratio 1.82
Interest Coverage 3.71 Dividend Yield 0.02%
Valuation
P/E Ratio 18.72 P/B Ratio 3.52
P/S Ratio 1.80 PEG Ratio 0.24
EV/EBITDA 13.78 Dividend Yield 0.02%
Market Cap 2.13B Enterprise Value 2.99B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Revenue 1.18B 1.15B 1.02B 942.91M 793.83M
Net Income 113.79M 62.37M 134.24M 209.58M 85.83M
EPS (Diluted) 2.11 1.16 2.49 3.89 1.59
Gross Profit 767.07M 704.14M 660.83M 620.69M 463.48M
Operating Income 216.93M 182.89M 243.69M 298.47M 136.85M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Total Assets 2.08B 2.16B 1.41B 1.41B 1.22B
Total Liabilities 1.47B 1.62B 880.34M 907.14M 899.81M
Shareholders' Equity 604.42M 539.21M 531.59M 497.32M 321.97M
Total Debt 979.61M 1.08B 516.45M 580.30M 606.80M
Cash & Equivalents 121.20M 158.72M 149.92M 160.32M 120.62M
Current Assets 593.50M 630.50M 533.95M 519.22M 400.05M
Current Liabilities 326.92M 394.49M 217.79M 155.61M 132.87M

Strategy Scores

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
Growth + Value Growth at a Reasonable Price (Peter Lynch)
#93 of 326
60

Recent Activity

Entered Growth at a Reasonable Price (Peter Lynch)
Mar 24, 2026